Following our earlier studies of ETV6 [5], we continued to investigate the molecular mechanism underlying its antitumor effects by utilizing prostate cancer cells derived from a prostate-specific Pten/Trp53 double-knockout mouse [24, 26]. This evidence concerns the gene PTEN and prostate cancer.